Trial Profile
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms VENICE I
- Sponsors AbbVie; AbbVie Germany
- 12 Oct 2022 The trial has been completed in Greece, Sweden, Belgium, Netherlands, Austria, Ireland, Finland, and Denmark.
- 25 Mar 2022 Status changed from active, no longer recruiting to completed.
- 16 Dec 2021 This trial has been completed in Germany, as per European Clinical Trials Database record.